Your browser doesn't support javascript.
loading
SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron
Roanne Keeton; Marius B Tincho; Amkele Ngomti; Richard Baguma; Ntombi Benede; Akiko Suzuki; Khadija Khan; Sandile Cele; Mallory Bernstein; Farina Karim; Sharon V Madzorera; Thandeka Moyo-Gwete; Mathilda Mennen; Sango Skelem; Marguerite Adriaanse; Daniel Mutithu; Olukayode Aremu; Cari Stek; Elsa du Bruyn; Mieke Van Der Mescht; Zelda de Beer; Talita R de Villiers; Annie Bodenstein; Gretha van den Berg; Adriano Mendes; Amy Strydom; Marietjie Venter; Alba Grifoni; Daniela Weiskopf; Alessandro Sette; Robert J Wilkinson; Linda-Gail Bekker; Glenda Gray; Veronica Ueckermann; Theresa Rossouw; Michael T Boswell; Jinal Bihman; Penny Moore; Alex Sigal; Ntobeko A. B. Ntusi; Wendy A Burgers; Catherine Riou.
Afiliación
  • Roanne Keeton; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; Division of Medical Virology, Department of Patholo
  • Marius B Tincho; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; Division of Medical Virology, Department of Patholo
  • Amkele Ngomti; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; Division of Medical Virology, Department of Patholo
  • Richard Baguma; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; Division of Medical Virology, Department of Patholo
  • Ntombi Benede; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; Division of Medical Virology, Department of Patholo
  • Akiko Suzuki; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; Division of Medical Virology, Department of Patholo
  • Khadija Khan; Africa Health Research Institute, Durban, South Africa; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
  • Sandile Cele; Africa Health Research Institute, Durban, South Africa; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
  • Mallory Bernstein; Africa Health Research Institute, Durban, South Africa; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
  • Farina Karim; Africa Health Research Institute, Durban, South Africa; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
  • Sharon V Madzorera; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; SA MRC Antibody Immunity Research Unit, Scho
  • Thandeka Moyo-Gwete; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; SA MRC Antibody Immunity Research Unit, Scho
  • Mathilda Mennen; Department of Medicine, University of Cape Town and Groote Schuur Hospital, Observatory, South Africa
  • Sango Skelem; Department of Medicine, University of Cape Town and Groote Schuur Hospital, Observatory, South Africa
  • Marguerite Adriaanse; Department of Medicine, University of Cape Town and Groote Schuur Hospital, Observatory, South Africa
  • Daniel Mutithu; Department of Medicine, University of Cape Town and Groote Schuur Hospital, Observatory, South Africa
  • Olukayode Aremu; Department of Medicine, University of Cape Town and Groote Schuur Hospital, Observatory, South Africa
  • Cari Stek; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; Department of Medicine, University of Cape Town and
  • Elsa du Bruyn; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; Department of Medicine, University of Cape Town and
  • Mieke Van Der Mescht; Department of Immunology, University of Pretoria, Pretoria, South Africa
  • Zelda de Beer; Tshwane District Hospital, Tshwane, South Africa
  • Talita R de Villiers; Tshwane District Hospital, Tshwane, South Africa
  • Annie Bodenstein; Tshwane District Hospital, Tshwane, South Africa
  • Gretha van den Berg; Tshwane District Hospital, Tshwane, South Africa
  • Adriano Mendes; Centre for Viral Zoonoses, Department of Virology, University of Pretoria, Pretoria, South Africa
  • Amy Strydom; Centre for Viral Zoonoses, Department of Virology, University of Pretoria, Pretoria, South Africa
  • Marietjie Venter; Centre for Viral Zoonoses, Department of Virology, University of Pretoria, Pretoria, South Africa
  • Alba Grifoni; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA
  • Daniela Weiskopf; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA
  • Alessandro Sette; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, USA; Department of Medicine, Division of Infectious
  • Robert J Wilkinson; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; Department of Medicine, University of Cape Town and
  • Linda-Gail Bekker; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; Department of Medicine, University of Cape Town and
  • Glenda Gray; South African Medical Research Council, Cape Town, South Africa
  • Veronica Ueckermann; Department of Internal Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa
  • Theresa Rossouw; Department of Immunology, University of Pretoria, Pretoria, South Africa
  • Michael T Boswell; Department of Internal Medicine, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa
  • Jinal Bihman; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; SA MRC Antibody Immunity Research Unit, Scho
  • Penny Moore; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; National Institute for Communicable Diseases of the
  • Alex Sigal; Africa Health Research Institute, Durban, South Africa; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; M
  • Ntobeko A. B. Ntusi; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; Department of Medicine, University of Cape Town and
  • Wendy A Burgers; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; Division of Medical Virology, Department of Patholo
  • Catherine Riou; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa; Division of Medical Virology, Department of Patholo
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21268380
ABSTRACT
The SARS-CoV-2 Omicron variant has multiple Spike (S) protein mutations that contribute to escape from the neutralizing antibody responses, and reducing vaccine protection from infection. The extent to which other components of the adaptive response such as T cells may still target Omicron and contribute to protection from severe outcomes is unknown. We assessed the ability of T cells to react with Omicron spike in participants who were vaccinated with Ad26.CoV2.S or BNT162b2, and in unvaccinated convalescent COVID-19 patients (n = 70). We found that 70-80% of the CD4 and CD8 T cell response to spike was maintained across study groups. Moreover, the magnitude of Omicron cross-reactive T cells was similar to that of the Beta and Delta variants, despite Omicron harbouring considerably more mutations. Additionally, in Omicron-infected hospitalized patients (n = 19), there were comparable T cell responses to ancestral spike, nucleocapsid and membrane proteins to those found in patients hospitalized in previous waves dominated by the ancestral, Beta or Delta variants (n = 49). These results demonstrate that despite Omicrons extensive mutations and reduced susceptibility to neutralizing antibodies, the majority of T cell response, induced by vaccination or natural infection, cross-recognises the variant. Well-preserved T cell immunity to Omicron is likely to contribute to protection from severe COVID-19, supporting early clinical observations from South Africa.
Licencia
cc_by
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies / Observational_studies / Prognostic_studies / Rct Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies / Observational_studies / Prognostic_studies / Rct Idioma: En Año: 2021 Tipo del documento: Preprint